3Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug - resistant, including extended - spectrum β - lactamase producing, Enterobacteriaceae infections: a systematic review [ J ]. Lancet Infect Dis, 2010 ; 10 : 43 - 50.
4Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase - producing bacteria [J]. Lancet Infect Dis, 2009 ; 9 : 228 - 236.
5Xiao Y, Wang J, Li Y. Bacterial resistance surveillance in China: a report from Mohnarin 2004 - 2005 [ J]. Eur J Clin Micro- biol Infect Dis, 2008 ;27 : 697 -708.
6Clinical and Laboratory Standards Institute. PerformanceStandards for Antimicrobial Susceptibility Testing[ S]. Eighteenth Informational Supplement, M100 - S18, 2008.
7Zhanel GG, Laing NM, Nichol KA, et al. Antibiotic activity against urinary tract infecttion isolates of vancomycin resistant enterococci results from the 2002 North American Vancomycin Resistant Enterococci Susceptibility Study [ J]. J Antimicrob Chemother ,2003 ;52:382 -388.
8Clinical and Laboratory Standard Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. Wayne: Clincial and Laboratory Standards Institute. 2010.
